

Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.

P Costelli, ... , F M Baccino, J M Argilés

J Clin Invest. 1995;**95**(5):2367-2372. <https://doi.org/10.1172/JCI117929>.

Research Article

Tissue protein hypercatabolism (TPH) is a most important feature in cancer cachexia, particularly with regard to the skeletal muscle. The rat ascites hepatoma Yoshida AH-130 is a very suitable model system for studying the mechanisms involved in the processes that lead to tissue depletion, since it induces in the host a rapid and progressive muscle waste mainly due to TPH (Tessitore, L., G. Bonelli, and F. M. Baccino. 1987. *Biochem. J.* 241:153-159). Detectable plasma levels of tumor necrosis factor-alpha associated with marked perturbations in the hormonal homeostasis have been shown to concur in forcing metabolism into a catabolic setting (Tessitore, L., P. Costelli, and F. M. Baccino. 1993. *Br. J. Cancer.* 67:15-23). The present study was directed to investigate if beta 2-adrenergic agonists, which are known to favor skeletal muscle hypertrophy, could effectively antagonize the enhanced muscle protein breakdown in this cancer cachexia model. One such agent, i.e., clenbuterol, indeed largely prevented skeletal muscle waste in AH-130-bearing rats by restoring protein degradative rates close to control values. This normalization of protein breakdown rates was achieved through a decrease of the hyperactivation of the ATP-ubiquitin-dependent proteolytic pathway, as previously demonstrated in our laboratory (Llovera, M., C. García-Martínez, N. Agell, M. Marzábal, F. J. López-Soriano, and J. M. Argilés. 1994. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 338:311-318). By contrast, the drug did [...]

Find the latest version:

<https://jci.me/117929/pdf>



Muscle Protein Waste in Tumor-bearing Rats Is Effectively Antagonized by a β_2 -Adrenergic Agonist (Clenbuterol)

Role of the ATP-Ubiquitin-dependent Proteolytic Pathway

Paola Costelli,* Célia García-Martínez,[‡] Marta Llovera,[‡] Neus Carbó,[‡] Francisco J. López-Soriano,[‡] Neus Agell,[§] Luciana Tessitore,* Francesco M. Baccino,*^{||} and Josep M. Argilés[‡]

[‡]Departament de Bioquímica i Fisiologia, Facultat de Biologia, and [§]Departament de Biologia Cel·lular, Facultat de Medicina, Universitat de Barcelona, 08071 Barcelona, Spain; *Dipartimento di Medicina ed Oncologia Sperimentale, Sezione di Patologia Generale, Università di Torino, 10125 Torino, Italy; and ^{||}Centro CNR di Immunogenetica ed Oncologia Sperimentale, 10125 Torino, Italy

Abstract

Tissue protein hypercatabolism (TPH) is a most important feature in cancer cachexia, particularly with regard to the skeletal muscle. The rat ascites hepatoma Yoshida AH-130 is a very suitable model system for studying the mechanisms involved in the processes that lead to tissue depletion, since it induces in the host a rapid and progressive muscle waste mainly due to TPH (Tessitore, L., G. Bonelli, and F. M. Baccino. 1987. *Biochem. J.* 241:153–159). Detectable plasma levels of tumor necrosis factor- α associated with marked perturbations in the hormonal homeostasis have been shown to concur in forcing metabolism into a catabolic setting (Tessitore, L., P. Costelli, and F. M. Baccino. 1993. *Br. J. Cancer.* 67:15–23). The present study was directed to investigate if β_2 -adrenergic agonists, which are known to favor skeletal muscle hypertrophy, could effectively antagonize the enhanced muscle protein breakdown in this cancer cachexia model. One such agent, i.e., clenbuterol, indeed largely prevented skeletal muscle waste in AH-130-bearing rats by restoring protein degradative rates close to control values. This normalization of protein breakdown rates was achieved through a decrease of the hyperactivation of the ATP-ubiquitin-dependent proteolytic pathway, as previously demonstrated in our laboratory (Llovera, M., C. García-Martínez, N. Agell, M. Marzábal, F. J. López-Soriano, and J. M. Argilés. 1994. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 338:311–318). By contrast, the drug did not exert any measurable effect on various parenchymal organs, nor did it modify the plasma level of corticosterone and insulin, which were increased and decreased, respectively, in the tumor hosts.

Address correspondence to Dr. Josep M. Argilés, Unitat de Bioquímica i Biologia Molecular B, Departament de Bioquímica i Fisiologia, Facultat de Biologia, Universitat de Barcelona, Diagonal 645, 08071-Barcelona, Spain. Phone: 3-4021519; FAX: 3-4021559.

Received for publication 11 July 1994 and in revised form 4 January 1995.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/95/05/2367/06 \$2.00

Volume 95, May 1995, 2367–2372

The present data give new insights into the mechanisms by which clenbuterol exerts its preventive effect on muscle protein waste and seem to warrant the implementation of experimental protocols involving the use of clenbuterol or alike drugs in the treatment of pathological states involving TPH, particularly in skeletal muscle and heart, such as in the present model of cancer cachexia. (*J. Clin. Invest.* 1995. 95:2367–2372.) Key words: clenbuterol • tumor • protein turnover • cachexia • ubiquitin

Introduction

Malignant neoplasms frequently induce a progressive loss of lean body mass in the host associated with marked alterations in the endocrine and metabolic homeostasis. The skeletal muscle, which accounts for almost half of the whole body protein mass, is severely affected in cancer cachexia (1–3) and evidence has been provided for muscle protein waste as being associated with enhanced turnover rates (4–9). Since cachexia tends to develop at a rather advanced stage of the neoplastic growth, preventing muscle waste in cancer patients is of a great potential clinical interest. Whether the negative protein balance results from altered rates of synthesis or breakdown or from changes on both sides of muscle protein turnover is still debated, however (6, 10–12).

The rat ascites hepatoma Yoshida AH-130 is a suitable model system to study the mechanisms involved in the establishment of cachexia. Its growth causes in the host rapid and progressive loss of body weight and tissue waste, particularly in skeletal muscle. Acceleration of tissue protein breakdown accounts for most of the waste in the AH-130 bearers (6, 13–15). In particular, skeletal muscle hypercatabolism is mainly due to hyperactivation of the ATP-ubiquitin-dependent proteolytic system (16). Detectable plasma levels of tumor necrosis factor- α (TNF) and perturbations in the hormonal homeostasis (17) likely play an important role in forcing the metabolic balance towards the catabolic side.

β_2 -adrenergic agonists are potent muscle growth promoters in many animal species (18), resulting in skeletal muscle hypertrophy, while they cause a reduction of the body fat content (19). These compositional alterations are associated with a redistribution of energy substrates, which are mobilized from storage sites for utilization by tissues such as muscle and brown adipose tissue (19). The intimate mechanisms by which these

compounds exert such effects at the cellular level are still uncertain (19), although changes in protein turnover are clearly involved. Little is known, however, as to whether β_2 -agonists act by potentiating the anabolic processes or depressing the catabolic ones.

Aim of the present investigation has been to study the effects of a β_2 -adrenergic agonist (clenbuterol), well known for its selective anabolic action on the skeletal muscle, on tissue protein turnover in rats bearing a cachexia-generating fast-growing tumor.

Methods

Animals, tumor inoculation, and treatment. Male Wistar rats (Interfauna, Barcelona, Spain) weighing ~ 100 g were used. The animals were maintained on a regular light-dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free access to food and water. The diet (Panlab, Barcelona, Spain) consisted of 54% carbohydrate, 17% protein, and 5% fat (the residue was nondigestible material); the food intake was measured daily. Rats were divided into two groups, namely controls and tumor hosts. The latter received an intraperitoneal inoculum of 10^8 AH-130 Yoshida ascites hepatoma cells obtained from exponential tumors (for details see reference 6). Both groups were further divided into treated and untreated, the former being administered a daily s.c. dose of clenbuterol (1 mg/kg b.w., dissolved in physiological solution), the latter a corresponding volume of solvent.

On days 0, 4, and 8 after tumor transplantation animals were weighed and anesthetized with diethyl ether. The tumor was harvested from the peritoneal cavity, its volume and cellularity evaluated, and cells separated from the ascitic fluid by centrifugation at 100 g for 10 min. Blood was collected from the abdominal aorta into heparinized tubes and centrifuged (3500 g, 10 min, 4°C) to obtain plasma. Tissues were rapidly excised, weighed, and frozen in liquid nitrogen (see reference 6; for the adipose tissues see reference 20).

Protein turnover. Protein turnover rates were determined by a method that, as previously discussed (6, 15), is very suitable for the liver (21), yet suffers from considerable label recycling in skeletal muscle (22); however, it offers the best compromise to monitor simultaneously protein synthesis and degradation in the same animal (see reference 23). Briefly, apparent rates of synthesis and degradation for proteins of the slow turnover pool were evaluated by measuring the decay in specific and total protein radioactivity after labeling *in vivo*, 24 h before tumor transplantation, with a single intraperitoneal dose of sodium [14 C]bicarbonate (250 μ Ci/kg b.w.). Fractional rates of protein degradation (k_d), synthesis (k_s), and accumulation (k_a) were calculated as follows:

$$k_d = \ln(\text{total protein radioactivity})/t$$

$$k_s = \ln(\text{specific protein radioactivity})/t$$

$$k_a = \ln(\text{total protein})/t$$

and expressed as percent per day.

Tissue protein was determined by the method of Lowry et al. (24), using bovine serum albumin as working standard.

RNA isolation and Northern blot analysis. Total RNA from gastrocnemius muscle was extracted using the acid guanidinium isothiocyanate/phenol/chloroform method as described by Chomczynski and Sacchi (25). RNA samples (40 μ g/ml) were denatured, subject to 1.2% agarose gel electrophoresis and transferred to Hybond H membrane (Amersham International, Buckinghamshire, UK). RNA was fixed to membrane by illuminating with UV for 4 min.

Prehybridization was done in 50% formamide/5 \times SSC (0.3 M NaCl, 65 mM sodium citrate)/5 \times Denhart's solution (1 \times Denhart's solution is 0.1% polyvinylpyrrolidone, 0.1% Ficoll, 0.1% BSA)/20 mM sodium phosphate pH 6.8/0.1% SDS/100 μ g/ml denatured salmon sperm DNA overnight at 42°C. Membranes were hybridized with appro-

prate probes (10^6 – 10^7 cpm/ml) at 42°C for 18 h. Nonspecifically bound probe was removed by successive washes in 2 \times SSC (15 min at 55°C, twice), 2 \times SSC + 0.1% SDS (30 min at 55°C) and 0.1 \times SSC + 0.1% SDS (15 min at 55°C, twice). Specific hybridization was then detected by autoradiography (for more details see 16).

Radioabeled probes were prepared by the random priming method (Boehringer-Mannheim, Barcelona, Spain). The ubiquitin probe used was a cDNA clone containing 12 bp of the second ubiquitin coding sequence plus a complete third and fourth ubiquitin coding sequence and 120 bp of the 3'-untranslated region of the chicken polyubiquitin gene UB1 (26). An actin probe was used as a control of loading. Filters were exposed to X Omat AR-5 films (Eastman Kodak Co., Rochester, NY) at -70°C for 2–4 d.

Plasma hormones. Circulating corticosterone was evaluated by a rat radioimmunoassay (IDS, Boldon, England). Insulin was measured by radioimmunoassay by the method of Albano et al. (27), using rat insulin as working standard.

Data presentation. Data are given as means \pm SD. Two-way factorial analysis of variance was used to calculate the significance of differences. As for fractional rates of protein turnover, significance of differences was calculated by analysis of variance on linear regressions (28).

Chemicals. All enzymes and coenzymes were obtained from Boehringer-Mannheim or Sigma Chemical Co. (St. Louis, MO), sodium 14 C-bicarbonate (53 mCi/mmol) from New England Nuclear (Boston, MA). Clenbuterol was kindly provided by Smithkline Beechman Pharmaceuticals (Betchworth, Surrey, UK).

Results

The rat ascites hepatoma Yoshida AH-130 grew exponentially for 4–5 d then shifted into a stationary phase approximately by day 8 after transplantation, as previously shown (29). This growth pattern was not significantly affected by clenbuterol (Table I).

Clenbuterol did not alter the food intake either in controls or in tumor bearers. The hypophagia occurring during tumor growth (15, 17) persisted unchanged in treated animals: the average daily food intake was 25 and 23 g on day 0, and 14, and 15 g on day 8 after tumor inoculation, respectively, in untreated and treated tumor hosts; in treated and untreated non-tumor bearing animals it amounted to 24 and 23 g, respectively, over the whole experimental period.

As shown in Table I, the loss of body weight in tumor bearers became prominent by day 8 and was not affected by clenbuterol. A marked reduction of white adipose tissue mass was already detectable at day 4 in clenbuterol-treated controls; this tissue was also diminished in day 8 tumor bearers, yet not further affected to a significant degree by the drug treatment. Both liver and brown adipose tissue were hypotrophic 4 d after tumor inoculation and even more so by day 8; no significant protective effect was exerted by clenbuterol on either tissue.

Quite different was the pattern with regard to skeletal and heart muscles. An early and progressive decrease in wet weight (data not shown) and protein content was elicited by tumor growth (Table II), with gastrocnemius and heart being affected earlier and more severely than soleus, as previously reported (6). Treatment with clenbuterol substantially prevented the protein waste in each tissue, since day 4 for gastrocnemius and heart, by day 8 for the soleus. This protective effect was also noticeable in terms of wet tissue weight for the skeletal muscles, but not for the heart (data not shown); a similar discrepancy between heart wet weight and protein content had already been observed in AH-130 tumor bearers treated with anti-TNF antibodies (30). In agreement with previous observations, clenbu-

Table I. Body and Tissue Weight and Tumor Growth in AH-130 Hosts after Clenbuterol Administration

Time	Tumor	Treatment	Body weight (g)			Liver	WAT	IBAT	Total tumor cell number ($\times 10^{-6}$)	Tumor volume
			Initial	Final						
					mg	mg	mg		ml	
Day 4	No	None	183±9	220±13	5725±164	397±41	163±21			
		Clenbuterol	189±6	217±8	5605±267	318±36	167±32			
	Yes	None	181±9	206±25	5168±320*	370±47	110±15*	2976±220	19±2	
		Clenbuterol	185±8	205±13	5051±275*	359±56	110±24*	2631±799	17±3	
Day 8	No	None	185±12	253±17	6437±267	564±31	162±23			
		Clenbuterol	182±12	216±23	6378±718	459±22	135±20			
	Yes	None	188±11	199±15 [‡]	4829±740 [‡]	421±23*	83±9 [‡]	8133±937	56±14	
		Clenbuterol	183±9	198±17 [‡]	4890±428 [‡]	381±68*	103±17 [‡]	7406±1206	51±15	

Data are expressed as means±SD. Tissue weights are expressed as percentages of initial body weight. Significance of the differences (two-way factorial analysis of variance): * $P < 0.05$; [‡] $P < 0.01$ (tumor burden) $n = 4$ and 6 for nontumor and tumor bearers, respectively.

terol afforded a significant trophic action (protein increase) on muscles in nontumor bearers as well, particularly on the gastrocnemius and less on the heart, while the soleus was not significantly affected (Table II).

Protein turnover in gastrocnemius and heart was evaluated to assess by which regulation, whether on synthesis or on degradation or both, the protein-sparing action of clenbuterol was exerted. As previously reported (6, 15), rates of protein degradation were enhanced in both muscles examined in consequence of tumor growth, while synthesis remained virtually unchanged, resulting in protein accumulation rates lower than in controls (Table III). On treatment with clenbuterol, the elevation of protein breakdown rates was suppressed and protein accumulation rates returned similar to those in controls (Table III). No detectable effect was observed with regard to protein synthesis rates. Likewise in nontumor bearers, the gastrocnemius and heart hypertrophy observed on drug treatment appeared to result from a marked decrease in protein catabolic rates, while synthesis rates were not significantly affected (Table III).

As previously shown (16), the accelerated muscle protein breakdown in the AH-130 hosts may be achieved through activation of the ATP-ubiquitin-dependent proteolytic system. As

shown in Fig. 1, two polyubiquitin mRNA species (2.4 and 1.2 kb) were found in gastrocnemius muscle. Tumor-bearing animals showed an increased expression of the polyubiquitin genes in relation with the corresponding control animals: over severalfold (2.4 kb) and 14-fold (1.2 kb). When the tumor-bearing animals received clenbuterol, this activation was suppressed, the values obtained being over twice than those obtained in the untreated controls for both ubiquitin mRNA (Fig. 1).

Corticosterone was elevated and insulin decreased in the blood plasma of AH-130 hosts, as previously observed (17). When these animals were administered clenbuterol, neither insulin nor corticosterone changes were affected, suggesting that the drug effects were not mediated through these hormones. In nontumor bearers the treatment did not modify corticosterone, while insulin concentrations decreased below the control values (Table IV).

Discussion

Muscle protein waste is a main feature in cancer cachexia and, generally, is mostly ascribed to enhanced tissue protein catabolism (4–9, 15). So far, most therapeutic approaches to cancer cachexia have been designed on the assumption that tissue waste merely results from undernutrition or tumor-host competition, yet parenteral nutrition or overfeeding have proven to be only marginally or, at best, temporarily effective (31–33). Moreover, in some cases the tumor itself apparently took advantage of such regimen more than the patient (32, 34).

The rat tumor model used in the present study quickly causes progressive body weight loss and tissue protein waste, the latter associated with TPH (6, 15) likely mediated by production of cytokines such as TNF and alterations in the hormonal homeostasis (17). The beneficial effects of treatments with anti-TNF antibodies (30) or with drugs interfering with the development of TPH (35) have been previously reported. The present observations show that treatment of the AH-130 hosts with clenbuterol largely abolished the protein waste in the gastrocnemius and heart by restoring normal rates of protein degradation. This is in agreement with previous reports that β_2 -adrenergic agonists may antagonize the skeletal muscle depletion in different situa-

Table II. Muscle Protein Content

Time	Tumor	Treatment	Gastrocnemius	Soleus	Heart
Day 0	No	None	45.8±3.5	2.29±0.11	45.5±3.4
Day 4	No	None	70.6±1.4	2.70±0.08	62.2±2.3
		Clenbuterol	73.2±1.3	2.84±0.16	59.1±10.1
	Yes	None	60.4±3.9**	2.62±0.20	54.2±4.2*
		Clenbuterol	64.8±2.2 [‡]	2.89±0.26	67.3±9.1 [‡]
Day 8	No	None	87.8±2.7	3.51±0.24	67.2±4.3
		Clenbuterol	99.1±3.6*	3.44±0.31	74.1±3.2*
	Yes	None	55.7±4.1**	2.70±0.26**	55.8±6.0*
		Clenbuterol	78.1±3.8 [‡]	3.16±0.18 [‡]	87.6±9.4***

Data (means±SD) are expressed as mg of protein per whole organ. Statistical comparison of the data (two-way factorial analysis of variance) showed significant effects for both tumor burden and treatment. Interactions: * $P < 0.05$ and ** $P < 0.01$ (tumor bearing vs. nontumor bearing); [‡] $P < 0.05$ and ^{‡‡} $P < 0.01$ (treatment vs. placebo). $n = 4$ and 6 for nontumor and tumor bearers respectively.

Table III. Muscle Protein Turnover

	k_s	k_d	k_a
Gastrocnemius			
Controls	10.30	2.36	5.65
r	-0.992	-0.989	0.996
slope	-1.92±0.29	-32±1.16	3.98±0.19
Controls + clenbuterol	10.28	1.05**	7.18**
r	-0.986	-0.995	0.990
slope	-1.95±0.25	-15±2.41	5.38±0.86
F	5.51	396	21.32
AH-130	9.06	7.02**	-1.01**
r	-0.995	-0.991	-0.858
slope	-1.77±0.27	-79±7.53	-0.63±0.26
F	4.68	498	248
AH-130 + clenbuterol	8.86	2.43††	4.21††
r	-0.978	-0.994	0.966
slope	-1.75±0.17	-33±1.49	2.79±0.35
F	4.97	500	140
Heart			
Controls	10.81	6.54	4.46
r	-0.991	-0.994	0.993
slope	-2.15±0.44	-481±24	2.39±0.17
Controls + clenbuterol	10.45	3.25**	6.65**
r	-0.994	-0.998	0.996
slope	-2.08±0.50	-257±23	4.00±0.15
F	3.28	409	512
AH-130	12.94	9.87**	1.81**
r	-0.988	-0.990	-0.991
slope	-2.19±0.57	-639±99	-0.89±0.21
F	4.12	48.24	197
AH-130 + clenbuterol	10.63	6.96†	8.20††
r	-0.992	-0.987	0.990
slope	-2.12±0.46	-506±61	5.32±0.22
F	5.03	24.07	1560

For further details see Methods section. Fractional rates of protein synthesis (k_s), degradation (k_d) and accumulation (k_a) are expressed as percent per day ($n = 5$ for each time point) and were calculated over the time interval 0–8 d, since linearity of radioactivity decay during the experimental period (days 0-2-4-6-8) was tested. Variance between groups is indicated by SE of the slope ($t \times$ SE of the slope, t being the 95% value of student's t test for $n-2$ (see Lee and Lee) (28). Significance of the differences: ** $P < 0.01$ vs. controls; † $P < 0.05$ and †† $P < 0.01$ vs. AH-130.

tions. Thus clenbuterol markedly attenuates the muscle atrophy by denervation (36, 37) or by hindlimb suspension (38). Moreover, this drug can increase the skeletal muscle mass in mice with genetic muscle dystrophy (39). More recently, clenbuterol has been reported to accelerate the recovery of the skeletal muscle mass after challenge with bacterial lipopolysaccharides or surgical stress (40, 41).

It is not clear how these agents modulate tissue protein turnover, though some indirect evidence for an effect on protein catabolism has been provided. Reeds et al. (42) did not observe any change in the gastrocnemius protein synthesis rates after

dietary administration of clenbuterol to rats, and concluded that decreased breakdown had to be involved. An indirect confirmation that β_2 -agonists may act by reducing protein catabolism came from a recent study in which the intracellular amino acid content of rat gastrocnemius was shown to increase after treatment with metaproterenol (43). In addition, glutamine, and alanine were found to be released at reduced rates from isolated muscles in the presence of the β -adrenergic agonist isoprenaline (44). The present study is totally consistent with these previous reports. Both the prevention of muscle protein depletion in AH-130 tumor bearers and the increase of muscle protein mass in nontumor bearers afforded by clenbuterol appeared to result from regulations on the catabolic side, respectively, by restoring protein breakdown to normal rates or by reducing them to less than normal levels. Moreover, in agreement with previous reports (45, 46), the effects of the drug appeared more marked on a fast-twitch (gastrocnemius) than on a slow-twitch muscle (soleus). The trophic action of β_2 -adrenergic agonists is generally regarded as quite selective for the skeletal muscle (19, 38, 42). After treatment with such drugs, however, cardiac hypertrophy has been reported in some studies (42, 47), yet not in others (38). In the present study, clenbuterol administration exerted quite comparable effects on gastrocnemius and heart in both control and tumor-bearing animals.

The precise mechanisms by which intracellular proteins are degraded is largely unknown, although it is accepted that proteolysis may occur inside and outside the lysosomes. Lysosomal proteases, in particular cathepsins, do not seem to be largely involved in the degradation of myofibrillar proteins in rat skeletal muscle (35, 48). The ATP-ubiquitin-dependent proteolytic system is postulated to account for the turnover of short-lived proteins (49) or for abnormal proteins formed during stress such as heat-shock (50). However, it has been suggested that the activity of this system can also be related to the turnover of long-lived proteins such as those found in skeletal muscle (51). Recently, this proteolytic system has been involved in the perturbations of protein metabolism consequent to fasting and denervation atrophy (52). Previous studies from our laboratory have shown that the lysosomal pathway is only marginally involved in the development of muscle protein hypercatabolism in the AH-130 hosts (16, 35), while an important activation of the ATP-dependent proteolysis seems to be the leading mechanism (16). It is very interesting to observe that the preventive effect exerted by clenbuterol on the acceleration of muscle protein breakdown is due to complete repression of the hyperexpression of the ubiquitin mRNAs. The association between the increased ubiquitin gene expression and the proteolytic activity in this tumor model has been recently studied by our laboratory (53). Moreover, it is important to underline that in control rats receiving clenbuterol, the ubiquitin mRNAs expression is below the basal value. To the best of our knowledge, this is the first report showing that the effect of clenbuterol on muscle protein turnover is due to down-regulation of the ATP-ubiquitin-dependent proteolytic system.

β_2 -adrenergic agonists are also known to display their anabolic effects in different situations of perturbed endocrine status such as diabetes, adrenalectomy, or castration (47, 54), suggesting that their action might involve hormonal modulations. However, as far as insulin and corticosterone are concerned, the present study suggests that this is not the case for the AH-130 hosts, since the altered plasma level of neither hormone was corrected by the treatment. However, the hormonal involvement




Figure 1. Northern blots of gastrocnemius muscle extracts from tumor-bearing rats. Expression of ubiquitin mRNA in skeletal gastrocnemius muscles from control (C), control treated with clenbuterol (C+CL), 7-d tumor-bearing (TB) and 7-d tumor-bearing treated with clenbuterol (TB+CL). It was detected after hybridization with a cDNA probe containing a region of the chicken polyubiquitin gene UB1. Autoradiographs were subjected to scanning densitometry. Ethidium bromide (EtBr) was used for total RNA quantitation. The results of 3 different animals are shown and expressed as arbitrary units. Significance of the differences (two-way factorial analysis of variance): $P < 0.01$ (tumor burden); $P < 0.01$ (treatment).

cannot be ruled out since the β_2 -agonist could have altered hormone sensitivity (55).

Another important action of β_2 -adrenergic agonists is to reduce the body fat content by directly stimulating lipolysis (19); tissue-specific modulations in lipoprotein lipase activity could constitute an additional mechanism for promoting a decreased lipid accretion in adipose tissue (56). In addition, these drugs enhance the overall energy expenditure and increase the thermogenesis, thereby dissipating the excess energy derived from the lipids mobilized (19). The present cachexia model in itself is characterized by extensive lipid mobilization (20, 57), associated with decreased activity of tissue lipoprotein lipase (20). The lack of effect of clenbuterol on adipose tissue in AH-130 hosts thus probably reflects the fact that lipid mobilization was already occurring in these animals and could not be easily stimulated further. When the drug treatment was applied to control rats, however, the adipose tissue mass decreased with respect to untreated controls (by 20%), in agreement with previous reports (38, 58).

In conclusion, the present results indicate that clenbuterol

exerted a selective, powerful protective action on heart and skeletal muscle by antagonizing the enhanced protein degradation and the resulting protein loss that characterize cachexia in AH-130 tumor-bearing rats. These observations suggest that, in spite of its numerous side effects, clenbuterol could reveal as a convenient therapeutic tool in pathological states wherein muscle protein hypercatabolism is a critical feature such as cancer cachexia or other wasting diseases.

Acknowledgments

The authors would like to thank Smith Kline Beechman Pharmaceuticals (Betchworth, Surrey, UK), which kindly provided clenbuterol, and Dr. M. J. Schlesinger for providing the ubiquitin-specific probes.

This work was supported by grants from the Fondo de Investigaciones Sanitarias de la Seguridad Social (94/1048) of the Spanish Health Ministry, the Dirección General de Investigación Científica y Técnica (PB90-0497) from the Spanish Ministry of Education and Science, the Ministero dell'Università e della Ricerca Scientifica e Tecnologica (60 and 40% funds), Roma, the Consiglio Nazionale delle Ricerche (Special Project ACRO), Roma, the Associazione Italiana per la Ricerca sul Cancro, Milano. P.C. received a fellowship from the Centre Interdepartamental de Recerca i Innovació Tecnològica, Generalitat de Catalunya.

References

1. Lawson, D. H., A. Richmond, D. W. Nixon, and D. Rudman. 1982. Metabolic approaches to cancer cachexia. *Annu. Rev. Nutr.* 2:277-301.
2. Morrison, S. D. 1989. Cancer cachexia. In *Influence of Tumor Development on the Host*. A. L. Liotta, editor. Kluwer Academic Publisher, The Netherlands. 176-213.
3. Tisdale, M. J. 1992. Cancer cachexia. *Br. J. Cancer.* 63:337-342.
4. Kien, C. L., and B. M. Camitta. 1983. Increased whole-body protein turnover in children with newly diagnosed leukemia or lymphoma. *Cancer Res.* 43:5592-5596.
5. Kien, C. L., and B. M. Camitta. 1987. Close association of accelerated rates of whole body protein turnover (synthesis and breakdown) and energy expenditure in children with newly diagnosed acute lymphocytic leukaemia. *J. Parent. Ent. Nutr.* 11:129-134.
6. Tessitore, L., G. Bonelli, and F. M. Baccino. 1987. Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. *Biochem. J.* 241:153-159.

Table IV. Plasma Levels of Insulin and Corticosterone

Time	Tumor	Treatment	Corticosterone	Insulin
			mg/dl	μ U/ml
Days 4-8	No	None	156 \pm 37	200 \pm 26
Day 4	No	Clenbuterol	177 \pm 47	115 \pm 20
	Yes	None	463 \pm 156*	86 \pm 9*
	Yes	Clenbuterol	434 \pm 186*	70 \pm 10*
Day 8	No	Clenbuterol	167 \pm 42	151 \pm 13
	Yes	None	463 \pm 145*	98 \pm 11*
	Yes	Clenbuterol	580 \pm 171*	79 \pm 10*

Data are means \pm SD. Significance of the differences (two-way factorial analysis of variance): * $P < 0.05$ (tumor burden). $n = 4$ and 6 for nontumor and tumor bearers, respectively.

7. Beck, S. A., and M. J. Tisdale. 1989. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. *Cancer Res.* 49:3800–3804.
8. Melville, S., M. A. McNurlan, A. Graham Calder, and P. J. Garlick. 1990. Increased protein turnover despite normal energy metabolism and responses to feeding in patients with lung cancer. *Cancer Res.* 50:1125–1131.
9. Beck, S. A., K. L. Smith, and M. J. Tisdale. 1991. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. *Cancer Res.* 51:6089–6093.
10. Pain, V. M., D. P. Randall, and P. J. Garlick. 1984. Protein synthesis in liver and skeletal muscle of mice bearing an ascites tumor. *Cancer Res.* 44:1054–1057.
11. Lundholm, K., D. Ekman, S. Edstrom, I. Karlberg, R. Jagenberg, and T. Scherstén. 1979. Protein synthesis in liver tissue under the influence of a methylcholanthrene-induced sarcoma in mice. *Cancer Res.* 39:4657–4661.
12. Emery, P. W., A. M. Neville, R. H. T. Edwards, and M. J. Rennie. 1982. Increased myofibrillar degradation and decreased protein synthesis in tumor-bearing mice. *Eur. J. Clin. Invest.* 12:10.
13. Baccino, F. M., L. Tessitore, G. Bonelli, and C. Isidoro. 1986. Protein turnover states of tumour cells and host tissues in an experimental model. *Biomed. Biochim. Acta.* 45:1585–1590.
14. Tessitore, L., G. Bonelli, C. Isidoro, O. V. Kazakova, and F. M. Baccino. 1986. Comparative studies of protein turnover regulations in tumor cells and host tissues: development and analysis of an experimental model. *Toxicol. Pathol.* 14:451–456.
15. Tessitore, L., P. Costelli, G. Bonetti, and F. M. Baccino. 1993. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. *Arch. Biochem. Biophys.* 306:52–58.
16. Llovera, M., C. García-Martínez, N. Agell, M. Marzábal, F. J. López-Soriano, and J. M. Argilés. 1994. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 338:311–318.
17. Tessitore, L., P. Costelli, and F. M. Baccino. 1993. Humoral mediation for cancer cachexia in tumour-bearing rats. *Br. J. Cancer.* 67:15–23.
18. Stock, M. J., and N. J. Rothwell. 1985. Effects of β -adrenergic agonists on metabolism and body composition. In *Control and manipulation of Animal Growth*. P. J. Buttery, N. B. Hayes, and D. B. Lindsay, editors. Butterworths, London. 249–257.
19. Yang, Y. T., and M. A. McElligot. 1989. Multiple actions of β -adrenergic agonists on skeletal muscle and adipose tissue. *Biochem. J.* 261:1–10.
20. Carbó, N., P. Costelli, L. Tessitore, G. J. Bagby, F. J. López-Soriano, F. M. Baccino, and J. M. Argilés. 1994. Anti-TNF treatment interferes with changes in lipid metabolism in a tumour cachexia model. *Clin. Sci.* 87:349–355.
21. Swick, R. W., and M. M. Ip. 1974. Measurement of protein turnover in rat liver with [14 C]carbonate. Protein turnover during liver regeneration. *J. Biol. Chem.* 249:6836–6841.
22. MacDonald, M. L., S. L. Augustine, T. L. Burck, and R. W. Swick. 1979. A comparison of methods for the measurement of protein turnover in vitro. *Biochem. J.* 184:473–476.
23. Garlick, P. J., D. J. Millward, W. P. T. James, and J. C. Waterlow. 1975. The effect of protein deprivation and starvation on the rate of protein synthesis in tissues of the rat. *Biochim. Biophys. Acta.* 414:71–84.
24. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin reagent. *J. Biol. Chem.* 193:265–275.
25. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate phenol chloroform extraction. *Anal. Biochem.* 162:156–159.
26. Bond, U., and M. J. Schlesinger. 1985. Ubiquitin is a heat-shock protein in chicken-embryo fibroblasts. *Mol. Cell. Biol.* 5:949–956.
27. Albano, J. D. M., R. P. Ekins, G. Maritz, and R. C. Turner. 1972. A sensitive and precise radioimmunoassay of serum insulin. *Acta Endocrinol.* 70:487–509.
28. Lee, J. D., and T. D. Lee. 1982. In: *Statistic and Numerical Methods for Biologists*. Vol. 1. Van Nostrand Reinhold Company. 185–205.
29. Tessitore, L., G. Bonelli, G. Cecchini, J. S. Amenta, and F. M. Baccino. 1987. Regulation of protein turnover versus growth state: ascites hepatoma as a model for studies both in the animal and in vitro. *Arch. Biochem. Biophys.* 255:372–384.
30. Costelli, P., N. Carbó, L. Tessitore, G. J. Bagby, F. J. López-Soriano, J. M. Argilés, and F. M. Baccino. 1993. Tumor necrosis factor- α mediates changes in protein turnover in a rat cancer cachexia model. *J. Clin. Invest.* 92:2783–2789.
31. Moley, J. F., S. D. Morrison, C. M. Gorschboth, and J. A. Norton. 1988. Body composition changes in rats with experimental cancer cachexia: improvement with exogenous insulin. *Cancer Res.* 48:2784–2787.
32. Popp, M. B., S. C. Wagner, E. B. Enrione, and O. J. Brito. 1988. Host and tumor responses to varying rates of nitrogen infusion in the tumor-bearing rat. *Ann. Surg.* 207:80–89.
33. Shaw, J. H., and R. R. Wolfe. 1988. Whole-body protein kinetics in patients with early and advanced gastrointestinal cancer: the early response to glucose infusion and total parenteral nutrition. *Surgery.* 103:148–155.
34. Tayek, J. A., N. W. Istfan, C. T. Jones, K. J. Hamawy, B. R. Bistran, and G. L. Blackburn. 1986. Influence of the Walker 256 carcinosarcoma on muscle, tumor, and whole-body protein synthesis and growth rate in the cancer-bearing rat. *Cancer Res.* 46:5649–5654.
35. Tessitore, L., P. Costelli, and F. M. Baccino. 1994. Pharmacological interference with tissue hypercatabolism in tumor-bearing rats. *Biochem. J.* 299:71–78.
36. Maltin, C. A., P. J. Reeds, M. I. Delday, S. M. Hay, F. J. Smith, and G. E. Lobley. 1986a. Inhibition and reversal of denervation-induced atrophy by the β -agonist growth promoter, clenbuterol. *Biosci. Rep.* 6:811–818.
37. Maltin, C. A., S. M. Hay, M. I. Delday, P. J. Reeds, and R. M. Palmer. 1989. Evidence that the hypertrophic action of clenbuterol on denervated rat muscle is not propranolol sensitive. *Br. J. Pharmacol.* 96:817–822.
38. Emery, P. W., N. J. Rothwell, M. J. Stock, and P. D. Winter. 1984. Chronic effects of β_2 -adrenergic agonists on body composition and protein synthesis in the rat. *Biosci. Rep.* 4:83–91.
39. Rothwell, N. J., and M. J. Stock. 1985. Modification of body composition by clenbuterol in normal and dystrophic mice. *Biosci. Rep.* 5:755–760.
40. Choo, J. J., M. A. Horan, R. A. Little, and N. J. Rothwell. 1989. Muscle wasting associated with endotoxemia in the rat: modification by the β_2 -adrenoceptor agonist clenbuterol. *Biosci. Rep.* 9:615–621.
41. Carter, W. J., A. Q. Dang, F. H. Faas, and M. E. Lynch. 1991. Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. *Metabolism.* 40:855–860.
42. Reeds, P. J., S. M. Hay, P. M. Dorward, and R. M. Palmer. 1986. Stimulation of muscle growth by clenbuterol: lack of effect on protein biosynthesis. *Br. J. Nutr.* 56:249–256.
43. Rodríguez-Mariscal, M., A. S. Del Barrio, J. Larralde, and J. A. Martínez. 1993. Free intracellular and protein bound amino acids in tissues as affected by a mixed β -adrenergic agonist. *Experientia.* 49:308–312.
44. Garber, A. J., I. E. Karl, and D. M. Kipnis. 1976. Alanine and glutamine synthesis and release. IV. β -adrenergic inhibition of amino acid release. *J. Biol. Chem.* 251:851–857.
45. Maltin, C. A., M. I. Delday, and P. J. Reeds. 1986. The effects of a growth promoting drug, clenbuterol, on fibre frequency and area in hindlimb muscles from young male rats. *Biosci. Rep.* 6:293–299.
46. Zeman, R. J., R. Ludemann, T. G. Easton, and J. D. Etlinger. 1988. Slow to fast alterations in skeletal muscle caused by clenbuterol, a β -receptor agonist. *Am. J. Physiol.* 254:E726–E732.
47. Deshaies, Y., J. Willemot, and J. Leblanc. 1981. Protein synthesis, amino acid uptake, and pools during isoproterenol-induced hypertrophy of the rat heart and tibialis muscle. *Can. J. Physiol. Pharmacol.* 59:113–121.
48. Lowell, B. B., N. B. Ruderman, and M. N. Goodman. 1986. Evidence that lysosomes are not involved in the degradation of myofibrillar proteins in rat skeletal muscle. *Biochem. J.* 234:237–240.
49. Ciechanover, A., D. Finley, and A. Varshavsky. 1984. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. *Cell.* 37:57–66.
50. Bond, U., N. Agell, A. L. Haas, K. Redman, and M. J. Schlesinger. 1988. Ubiquitin in stressed chicken embryo fibroblasts. *J. Biol. Chem.* 263:2384–2388.
51. Hilenski, L. L., L. Terracio, A. L. Haas, and T. K. Borg. 1992. Immunolocalization of ubiquitin conjugates at Z-bands and intercalated discs of rat cardiomyocytes in vitro and in vivo. *J. Histochem. Cytochem.* 40:1037–1042.
52. Wing, S. S., and A. L. Goldberg. 1993. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. *Am. J. Physiol.* 264:E668–E676.
53. Llovera, M., C. García-Martínez, N. Agell, F. J. López-Soriano, and J. M. Argilés. 1994. Muscle wastage associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. *Int. J. Cancer.* In press.
54. Rothwell, N. J., and M. J. Stock. 1988. Increased body weight gain and body protein in castrated or adrenalectomized rats treated with clenbuterol. *Br. J. Nutr.* 60:355–360.
55. Scheidegger, K., D. C. Robbins, and E. Danforth. 1984. Effects of chronic β -receptor stimulation on glucose metabolism. *Diabetes.* 33:1144–1149.
56. Belahsen, R., and Y. Deshaies. 1992. Modulation of lipoprotein lipase activity in the rat by the β_2 -adrenergic agonist clenbuterol. *Can. J. Physiol. Pharmacol.* 70:1555–1562.
57. Dessì, S., B. Batetta, C. Anchisi, P. Pani, P. Costelli, L. Tessitore, and F. M. Baccino. 1992. Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). *Br. J. Cancer.* 66:787–793.
58. Portillo, M. P., J. A. Martínez, and J. Larralde. 1991. Modifications homéorhétiques produites par un β -agoniste dans les tissus musculaires et adipeux chez le rat. *Reprod. Nutr. Dev.* 31:509–519.